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Abstract: Until recently, autoimmune diseases had been categorized as either Th1- or 
Th2-  mediated diseases. However, the discovery of a novel subset of helper T cells producing 
  interleukin (IL)-17, ie, Th17 cells, changed this paradigm. Currently, IL-17 and Th17 cells 
are implicated in many autoimmune diseases, such as rheumatoid arthritis, psoriasis,   multiple 
  sclerosis, and inflammatory bowel diseases. Such conclusions were initially drawn from 
  observations in animal models of autoimmune diseases, and accumulating data from clinical 
research also support the involvement of IL-17 in human diseases as well. Reagents targeting 
Th17-related molecules have been under clinical investigation for some diseases but have 
not always been effective in controlling disease activity. Consistent with this, it has become 
evident that there are substantial differences in the development of Th17 cells and in the way 
they function in autoimmune diseases between humans and experimental animals. Thus, further 
investigation is needed before we can draw any conclusions about the importance of IL-17 and 
Th17 cells in human autoimmune diseases.
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Introduction
The introduction of biologicals for treatment of autoimmune disorders has dramati-
cally changed the prognosis of these diseases. However, there are patients who are 
refractory to this treatment, and the frequency of patients who achieve drug-free 
remission is very low. This might indicate limitation of the current therapy targeting 
nonspecific inflammatory cytokines, such as tumor necrosis factor-alpha (TNFα). 
Therefore, development of a novel treatment strategy targeting molecules or cells that 
are closer to the etiology of autoimmune diseases is desired. Until recently, it was 
widely accepted that autoimmune diseases are categorized as Th1- or Th2-mediated 
diseases. The former includes Crohn’s disease (CD), psoriasis, rheumatoid arthritis 
(RA), and multiple sclerosis (MS), while the latter includes asthma, systemic lupus 
erythematosus (SLE), and ulcerative colitis (UC). However, the Th1/Th2 paradigm 
of autoimmune diseases included substantial discrepancies and was questioned by the 
discovery of a novel helper T cell subset, ie, Th17 cells, producing interleukin (IL)-17, 
firstly in mice, and a couple of years later in humans. Currently, many autoimmune 
diseases are believed to be Th17-mediated diseases, because the biologic functions 
of IL-17 are consistent with the chronic and destructive nature of inflammation. This 
review introduces accumulating evidence on the roles of IL-17 and Th17 cells in 
human autoimmune diseases.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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Biology of IL-17
IL-17 (IL-17A) was discovered in 1993 originally as a rodent 
T cell cDNA transcript, cytotoxic T lymphocyte-associated 
antigen 8 (CTLA8).1 Human IL-17 was subsequently 
  identified.2 To date, five additional members of the IL-17 
family have been identified and termed IL-17B, C, D, E, 
and F. IL-17F is most closely related to IL-17, and can form 
a heterodimer with IL-17, while IL-17E, also named IL-25, 
is instead classified as a Th2 cytokine.3 There are five receptors 
for the IL-17 family of cytokines, ie, IL-17RA, RB, RC, RD, 
and RE, of which IL-17RA and RC mediate the biologic 
activity of IL-17. While IL-17 is produced mainly by T cells, 
its receptor is expressed ubiquitously on   various cell types, 
including myeloid cells, epithelial cells, and fibroblasts. 
Therefore, IL-17 exerts various biologic functions in vivo, 
which might be involved in the pathogenesis of a wide range 
of inflammatory disorders, as well as infectious conditions 
(Figure 1).
One of the well-defined functions of IL-17 is mobilization 
of neutrophils, which is mediated by the production of CXC 
chemokines, including IL-8 (CXCL8) and growth-regulated 
oncogene-alpha (GROα, CXCL1), and growth factors, 
including granulocyte colony-stimulating factor (G-CSF) 
and granulocyte macrophage colony-stimulating factor 
  (GM-CSF), from epithelial cells and smooth muscle cells, 
as well as fibroblasts.3,4 In fact, murine models of infection 
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Figure 1 effects of IL-17 signaling on host defense, inflammation, and tissue destruction.
Abbreviations: BBB, blood-brain barrier; G-CSF, granulocyte colony stimulating factor; GM-CSF granulocyte macrophage colony stimulating factor; veGF, vascular 
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showed the involvement of IL-17 in neutrophil-mediated 
host defense against extracellular bacteria and fungi, such 
as Klebsiella pneumoniae, Escherichia coli, and Candida 
albicans.5 A role for IL-17 in mycobacterial infection, in 
which macrophage activation is important for host defense, 
was also reported. Furthermore, IL-17 participates in the 
elimination of pathogens by inducing antimicrobial peptides, 
such as β-defensins, especially in cooperation with IL-22.6 
Some studies suggest the role of IL-17 in human host defense 
mechanisms as well. Acosta-Rodriguez showed that human 
memory T cells specific for C. albicans produced IL-17.7 
Patients with hyper-IgE syndrome, who are defective in 
IL-17 production, are susceptible to bacterial and fungal 
infections.8
IL-17 exerts various biologic activities, which potentially 
cause tissue destruction and degeneration during chronic 
inflammation. IL-17 stimulates macrophages to produce 
various inflammatory cytokines, such as IL-1β and TNFα.9 
Furthermore, IL-17 acts synergistically with TNFα in IL-6 
and GM-CSF production from fibroblasts.4 Of particular 
importance in the pathogenesis of RA is that IL-17 induces 
cartilage destruction via induction of metalloproteinases and 
inhibition of proteoglycan synthesis. IL-17 induces expres-
sion of RANKL on osteoblasts that mediates osteoclasto-
genesis, leading to bone destruction in RA.10,11 Regarding 
intestinal inflammation, IL-17 stimulated metalloproteinase, 
IL-6, and IL-8 production from cultured colonic subepithelial 
myofibroblasts.12 IL-17 also upregulates production of GM-
CSF, IL-6, and GRO-α from keratinocytes.13 In the central 
nervous system, IL-17 was shown to disrupt the blood-brain 
barrier tight junction, which facilitated local migration of 
CD4 T cells.14 All these findings suggest an involvement of 
IL-17 in the pathogenesis of various autoimmune diseases 
affecting a number of tissues.
Th17 cells
As is the case for most T cell-derived effector cytokines, an 
initial study demonstrated IL-17 production by CD45RO+ 
memory T cells.4 Subsequently IL-17 was shown to be pro-
duced by Th1, Th0, and even Th2 cell clones.13,15 However, 
later studies in mice demonstrated by flow cytometric analysis 
of intracellular cytokine staining that IL-17-producing cells 
are characterized as a subset of helper T cells, which do not 
produce interferon gamma (IFNγ) or IL-4, the development 
of which was negatively regulated by IFNγ and IL-4, which 
are prototypic cytokines of Th1 and Th2 cells, respectively.3 
Thus, IL-17-producing CD4 T cells, which have been 
identified as a novel helper CD4 T cell subset distinct from 
Th1 and Th2 cells, were subsequently named Th17 cells. 
  Identification of human Th17 cells was also reported a couple 
of years later.7,16
Since the discovery of Th17 cells, the molecular mechanisms 
for their differentiation have been extensively studied. Initial 
studies showed that IL-23, a member of the IL-12 family of 
cytokines that consists of the common IL-12/23p40 subunit 
and the unique IL-23p19 subunit, induced differentiation 
of mouse Th17 cells. However, it was later suggested 
that IL-23 is involved in the maintenance, expansion, and 
functional maturation of Th17 cells. On the other hand, it is 
now widely accepted that naive mouse CD4 T cells primed 
with antigenic stimulation in the presence of transforming 
growth factor beta (TGFβ) and IL-6 differentiate into Th17 
cells. IL-21, which is produced by Th17 cells, can substitute for 
IL-6 in the differentiation of Th17 cells in an autocrine man-
ner.3   Resulting downstream signaling events that include 
activation of STAT3, induce the expression of RORγt and 
RORα, the master regulators of Th17 differentiation.17 
Human Th17 cells also express the human ortholog of murine 
RORγt, RORC2.18 T cells in patients with mutated STAT3 
are unable to differentiate into Th17 cells.8 However, there 
seem to be substantial differences in the signal requirement 
for the differentiation of mouse and human Th17 cells. In 
mice, IL-23 does not directly induce the differentiation of 
Th17 cells. However, IL-23, in combination with IL-1β, was 
repeatedly reported to play central roles in the differentiation 
of human Th17 cells, while the requirement for TGFβ in 
human Th17 differentiation is still controversial.3 Different 
sensitivity to TGFβ in the serum used for in vitro culture 
and different cellular sources used for the experiments are 
possible   explanations for this discrepancy. Alternatively, 
TGFβ indirectly promotes Th17 development by   inhibiting 
Th1 responses.19 Interestingly, human Th17 cells were dem-
onstrated to originate from CD161+ cells.20 CD161 is the 
human homolog of NK1.1 in mice. However, neither mouse 
Th17 cells nor IL-17-producing invariant NKT cells express 
NK1.1.21 Thus, there are substantial differences between 
human and mouse Th17 cells.
Expression of CCR6 is a common feature of mouse and 
human Th17 cells,7,16,22 although it should be kept in mind 
that not all CCR6-positive cells are Th17 cells. Th17 cells 
migrate toward CCL20, the ligand for CCR6, but also secrete 
CCL20. Therefore, there might be a positive feedback loop 
of chronic accumulation of Th17 cells once inflammation is 
provoked. Th17 cells produce several kinds of inflammatory 
cytokines in addition to IL-17 and IL-17F, which include 
TNFα and IL-6, IL-21, IL-22, and IL-26. It is worth noting Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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that not only IL-6 and TNFα, but also other cytokines, can be 
produced by other subsets of CD4 T cells. For example, IL-21 
is more likely a product of follicular helper T cells, which can 
be derived from Th1 and Th2 cells as well.23 In addition, not 
all IL-17-producing cells are positive for IL-21. Similarly, 
a large part of the IL-22-producing cell population does not 
belong to Th17 cells and is regarded as another independent 
subset of helper T cells, denoted as Th22 cells.24 Neverthe-
less, it is important to note that IL-22 and IL-17 cooperatively 
enhance expression of antimicrobial peptides.6 IL-22 is 
known to induce hyperplasia of keratinocytes involved in the 
pathogenesis of psoriasis (see below). IL-23 is also involved 
in IL-22 production. Thus, there are functional similarities 
between IL-17 and IL-22-producing T cells. As mentioned 
previously, IFNγ suppresses the differentiation of Th17 cells 
in vitro. However, presence of CD4 T cells producing both 
IL-17 and IFNγ has also been noted, especially in humans. 
Their origin and functions are not   clarified yet, but phenotypic 
plasticity of Th17 to Th1 cells by IL-12-signaling has been 
demonstrated.16
In addition to Th17 cells, other subset of T cells, including 
CD8 T, NK T, and TCRγδ T cells, have been demonstrated to 
produce IL-17 in mice. Even non-T cells, such as neutrophils 
and lymphoid tissue inducer-like cells, can also be an innate 
source of IL-17.25 Among them, γδ T cells are the most well 
known as an important source of in vivo IL-17 production 
in some circumstances, not limited to infection conditions,5 
but even in autoimmune diseases.26,27 IL-17 production by 
γδ T cells as well as other populations of non-Th17 cells has 
also been reported in human, but its importance has yet to 
be determined.
Implication of IL-17 and Th17 cells 
in autoimmune diseases
Inflammatory bowel diseases
CD and UC are the two major inflammatory bowel   diseases 
(IBDs). Although CD and UC share some features, there 
are clear differences in the areas of involvement as well 
as   histology, which are at least in part explained by their 
  different cytokine profiles. Thus, it has been widely accepted 
that CD and UC are Th1 and Th2 diseases,   respectively.28 
  Accordingly, animal models of IBD have also been 
  subdivided into Th1 and Th2 types as the models of CD 
and UC, respectively. However, the discovery of Th17 cells 
have provided novel insight into the pathogenesis of IBD. 
It was revealed that IL-23 is essential for the development 
of T cell-dependent IBD models, in which IBD is induced 
by   transferring naive CD4 T cells into RAG-deficient mice 
or developed spontaneously in IL-10-deficient mice.29,30 
The latter is of particular interest, because it was recently 
reported that the CD-associated mutation of the NOD2 gene 
suppresses IL-10 transcription.31 Neutralization of IL-23 
exerted a therapeutic effect on the development of experi-
mental colitis.32 These findings suggest the involvement 
of Th17 cells in the development of IBD mouse models. 
However, a protective role of IL-17 was also reported in the 
naive CD4 T cell-transfer model of colitis,33 although IL-17F 
might have opposite functions.34 Thus, the disease-promoting 
effect of IL-23 might not necessarily mediate IL-17 or Th17 
cells. Actually, it was observed that the lack of IL-23 also 
reduced Th1 responses, and that blocking IFNγ abrogated 
the development of the T cell transfer model of colitis.35 
Furthermore, IL-23 promoted even T cell-independent 
models of colitis.29
Despite the controversies about the importance of the 
IL-23/IL-17 axis in IBD animal models, there have been 
reports showing overexpression of Th17-related molecules in 
human IBD lesions (see Table). IL-17 mRNA was expressed 
in inflamed colonic tissue from CD or UC.36 Expression of 
IL-17 in the intestine of CD and UC was also demonstrated 
by immunohistochemistry, in which highest levels of expres-
sion were detected in the active CD lesion.37 Expression of 
IL-23p19 was increased in inflamed mucosa.38,39 There are 
studies addressing other Th17-related cytokines. IL-22 was 
shown to be overexpressed in inflamed mucosa and serum 
Table 1 expression pattern of IL-17 and IL-23 transcripts in lesional 
tissue samples
IL-17 IL-23p19 IL-12/23p40 Study (Ref)
IBD + + ± Neilsen et al36
Fujino et al37
Schmidt et al38
Holtta et al39
Kobayashi et al47
Psoriasis + + + Teunissen et al50
Lowes et al51
Chan et al52
wilson et al53
Piskin et al58
Zaba et al129
RA -/+ + -/± Chabaud et al77
Kirkham et al85
Stamp et al86
Hillyer et al87
Kohno et al88
Brentano94
MS + + + Lock et al104
Li et al110
Abbreviations:  IBS,  irritable  bowel  syndrome,  RA,  rheumatoid  arthritis;  ref, 
reference; MS, multiple sclerosis.Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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of CD patients.40,41 IL-17F mRNA was also expressed at a 
higher level especially in UC.42 An involvement of IL-23-
signaling in the pathogenesis of IBD was also suggested by 
its genetic association with IL23R polymorphisms.43 Genetic 
associations of CD with Tyk2 and STAT3, both of which are 
involved in IL-23-signaling, were also shown in a Japanese 
population.44
Human Th17 cells were first reported using samples from 
IBD patients, and there was an increase of IL-17+ cells in 
the gut of CD patients.16 Notably, many IL-17-producing 
T cells in the gut also produced IFNγ (about 40%). CD161+ 
Th17 cells are enriched in the lamina propria, even in 
healthy subjects, with a further increase in CD lesions.45 
The percentage of IL-17-producing cells in CD161 + CD4 
T cells in the peripheral blood also increased in CD patients. 
Interestingly, it was reported earlier that CD4 T cells in UC 
were enriched with IL-13-producing cells, which expressed 
CD161.46 Unfortunately, IL-17 production by CD161 + CD4 
T cells was not expected at that time and therefore was 
not examined. Kobayashi et al demonstrated an increased 
frequency of Th17 cells in the lamina propria compared 
with peripheral blood.47 Lamina propria CD4 T cells in 
UC produced more IL-17 than those in CD, while IFNγ 
production was higher in CD than in UC. The addition of 
IL-23 augmented both IL-17 and IFNγ production of LP 
CD4 T cells in vitro. It was also reported that the percentage 
of IL-17- and IFNγ-producing cells was higher in T cells 
in IBD lesions compared with control samples, but there 
was no difference between CD and UC.48 The number of 
  macrophages secreting IL-23, TNFα, and IL-6 increased in 
CD, and they affected IFNγ, but not IL-17, production of 
lamina propria mononuclear cells, suggesting the presence of 
an IL-23/IFNγ axis in the pathogenesis of CD.49 Therefore, 
although the relative importance of Th17 cells in human 
CD and UC is still unclear, IL-23 likely plays a critical role 
in the pathogenesis, which is now proved by the results of 
clinical trials described later in this paper.
Psoriasis
Psoriasis is a chronic inflammatory disease of the skin char-
acterized by epidermal hyperplasia, dermal angiogenesis, and 
inflammatory cell infiltrates. Psoriasis had been   generally 
regarded as a Th1 disease, but recent data suggest the 
  involvement of Th17 responses. Expression of IL-17 mRNA 
was detected in biopsies from lesional psoriatic skin.50–53 
Serum levels of IL-17 correlated with disease severity.54 Th17 
cells were detected in inflamed skin,51,53 although an increase 
of Th1 cells was also observed.55 The accumulation of Th17 
cells in psoriatic skin could be anticipated, because it was 
reported even before the discovery of Th17 that expression 
of CCL20 was upregulated in psoriatic skin, and skin-homing 
T cells express its receptor, CCR6.56 Keratinocytes, dermal 
fibroblasts, microvascular endothelial cells, and dendritic 
cells produce CCL20. As mentioned above, CCL20 is also 
produced by Th17 cells, which might account for the chro-
nicity of the disease.
Upregulation of IL-23 in psoriatic lesions was also repeat-
edly reported. Increased expression of IL-23p19 and IL-12/
IL-23p40 was noted in the lesional skin of psoriasis 
patients.52,57,58 Similar to IBD, association of the disease 
with the IL23R gene polymorphism was demonstrated.59,60 
The importance of IL-23 in the pathogenesis of psoriasis 
is also supported experimentally. Intradermal injection of 
IL-23 in mice induced psoriasis-like lesions with epidermal 
hyperplasia and inflammatory cellular infiltrate.52 Notably, 
TNFα, but not IL-17, was required for the response. It was 
later revealed that IL-22 mediates the IL-23-induced dermal 
pathology.61 Ma et al also demonstrated the requirement 
of IL-22 in another psoriasis model, which was induced 
by transferring naive CD4 T cells into scid/scid mice.62 
The IL-22 receptor was not expressed on immune cells 
but rather on epithelial keratinocytes, in which IL-22 
induced expression of antimicrobial peptides.63 IL-22 also 
regulates migration, proliferation, and differentiation of 
keratinocytes, suggesting roles of IL-22 in wound healing 
as well as skin inflammation.64 Furthermore, injecting IL-22 
directly into the skin induced expression of antimicrobial 
peptide, and inflammatory cytokines and keratinocyte 
hyperplasia.62 In agreement with these findings, serum IL-22 
levels increased in psoriasis patients and were correlated 
with disease severity.65 Local IL-22 expression increased in 
psoriatic lesions and was associated with increased expres-
sion of metalloproteinases and antimicrobial peptides.53,63,65 
Although Th17 cells can produce IL-22,6,61 IL-22 production 
by another independent subset of helper T cells in psoriatic 
lesions was recently reported by several groups.24,66,67 These 
IL-22-producing cells produce neither IL-17 nor IFNγ, 
but share similarities with Th17 cells in the expression 
pattern of chemokine receptors. However, their detailed 
characteristics and functions are yet to be analyzed. These 
findings suggest the importance of IL-23 and IL-22, pos-
sibly more than IL-17, in the pathogenesis of psoriasis. 
It is also suggested that IL-17 and IL-22 have a distinct 
function in the pathogenesis of psoriasis, ie, IL-22 regulates 
keratinocyte differentiation, while IL-17 is more related to 
inflammation.68Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
38
Yamada
Rheumatoid arthritis
RA is characterized by chronic inflammation of systemic 
synovial tissue, which leads to joint destruction. The well 
known disease association with major histocompatibility 
complex Class II genes and infiltration of CD4 T cells in 
synovial tissue implies that activation of autoreactive CD4 
T cells drives chronic inflammation. The requirement of 
CD4 T cells for the development of arthritis in animal mod-
els also supports the idea. Massive infiltration of activated 
macrophages in RA synovium suggests the involvement of 
Th1 cells, which are well known to activate macrophages 
in the host defense against intracellular pathogens. Expres-
sion of Th1 cytokines in RA joints was also demonstrated.69 
However, there has also been some data conflicting with the 
Th1 hypothesis, ie, mice blocking IFNγ-signaling were more 
susceptible to arthritis.70 Nevertheless, disease resistance of 
IL-12-deficient mice strongly argues in favor of the impor-
tance of Th1. However, it was later revealed that IL-23, 
which shares the p40 subunit with IL-12, but not IL-12, was 
required for the development of collagen-induced arthritis 
in an animal model of RA.71 Preserved IFNγ and defective 
IL-17 production in IL-23p19-deficient mice suggested the 
importance of IL-17 in the development of the disease. This 
was supported by findings that mice lacking IL-17 and mice 
in which IL-17 was blocked were less susceptible to collagen-
induced arthritis.72–74 Thereafter, the importance of IL-17 was 
demonstrated in many, if not all, animal models of arthritis, 
including spontaneous arthritis in IL-1Rα-deficient mice 
and the SKG strain of mice.75,76 These results suggest that 
Th17 cells are the pathogenic CD4 T cells driving chronic 
inflammation in human RA.
There have been numerous studies examining IL-17 
production in human RA. The first report by Chabaud et al 
detected bioactive IL-17 in the culture supernatants of 
  synovial cells.77 Immunohistochemical analysis demonstrated 
IL-17-positive cells in RA synovium, which accounted for 
about 1% of T cells. Consistent with this, a recent study 
demonstrated that the majority of IL-17-producing cells in 
RA synovium were mast cells, while there were relatively 
few IL-17-producing T cells.78 An earlier study, in which the 
concentration of IL-17 was measured by using polyclonal 
antibodies against IL-17, showed very high levels of IL-17 
in RA synovial fluid (SF) and serum.79 Although more recent 
studies also showed increased IL-17 production in RA SF 
compared with osteoarthritis SF,11,22,80,81 the levels were not 
as high as in the earlier report. Furthermore, a considerable 
portion of RA SF did not contain a detectable amount of 
IL-17. The concentration of IL-17 was even comparable 
between RA and osteoarthritis SF, but was increased in 
reactive arthritis and juvenile idiopathic arthritis.82,83 Raza 
et al reported that IL-17 production increased in the SF 
of early but not established RA.84 There are also several 
reports examining the expression of IL-17 transcripts in RA 
synovial membrane. Kirkham et al reported that increased 
levels of IL-17 mRNA expression predicted progression 
of joint damage,85 which fits well with the known biologic 
activity of IL-17. However, IL-17 mRNA was only detected 
in 15 of 54 RA patients, whereas IFNγ mRNA was detected 
in 48 of 56 patients. Others also detected IL-17 mRNA in 
only about half of RA samples.86,87 No difference was found 
in the expression level of IL-17 mRNA between RA and 
osteoarthritis by qualitative real-time polymerase chain reac-
tion.88 These findings are supported by studies examining the 
prevalence of Th17 cells by flow cytometry. The frequency of 
Th17 cells found in the peripheral blood of RA patients did 
not differ from controls,89,90 but was significantly increased 
in patients with psoriatic arthritis. Furthermore, Th1 cells 
predominated over Th17 cells in the joints,26,89 although the 
percentage of Th17 in CD4 T cells can be higher in joints 
than in blood, possibly due to the enrichment of CD45RO+ 
memory CD4 T cells. This is supported by earlier reports 
showing no increase of CCR6 expression in memory CD 4T 
cells in RA joints.91 In contrast with these findings, a recent 
report showed an increased proportion of Th17 cells in the 
peripheral blood of disease-modifying antirheumatic-drug 
naive RA patients.92 Together with the report by Raza et al 
this suggests the importance of Th17 at an early stage of the 
disease.84 A significant decrease of serum IL-17 after the 
onset of RA was also recently reported.93
Although IL-23 is even more important than IL-17 
for the development of animal models of arthritis, expres-
sion of IL-23 is not easily detected in RA. It was reported 
that the level of IL-23 protein in RA and osteoarthritis SF 
was comparably low, mainly due to defective IL-12/23p40 
expression.94 Stamp et al detected a low level of expression 
of IL-23p19 in RA synovial membrane, which was higher 
in the samples with IL-17 expression (13 of 25).86 There-
fore, unlike the case of CD or psoriatic lesions, IL-23 and 
IL-17 might not always be upregulated in RA synovium. In 
addition, it was reported that CD and psoriasis-associated 
variants of the IL23R gene are not associated with RA.95,96 
Of particular interest is the observation made by Hillyer et al 
that the addition of   anti-IL-23 monoclonal antibody (mAb) 
to the synovial cell culture only partly reduced IL-1β, TNFα, 
and IL-6 production.87 Furthermore, the effect of anti-IL-17 
mAb was even weaker than anti-IL-23 mAb. These results Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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were clearly different from what was shown two decades ago, 
ie, blocking TNFα in a similar culture system completely 
suppressed inflammatory cytokine production.97 Therefore, 
the importance of IL-17 in the pathogenesis of human RA 
could differ from that in animal models and remains an open 
question.
Multiple sclerosis
MS is an inflammatory demyelinating disease of the central 
nervous system. Experimental autoimmune encephalomyelitis 
(EAE) is an animal model of multiple sclerosis (MS) and is a 
prototype of T cell-mediated autoimmune disease. Thus, EAE 
is induced by either active immunization with myelin antigen 
or by adoptive transfer of myelin antigen-primed T cells, 
which enables us to address T cell functions easily. In fact, 
the importance of IL-23 in autoimmune inflammation was 
first demonstrated in this model,98 which led to the discovery 
of Th17 cells. However, the importance of the Th1 response 
in the pathogenesis of EAE was reevaluated more recently. 
While adoptive transfer of myelin-specific Th17 cells induced 
EAE characterized by neutrophil infiltration, Th1 cells trans-
ferred EAE with a macrophage-rich infiltrate.99 Expression 
of T-bet, irrespective of Th1 or Th17, was important for 
encephalitogenicity.100 Furthermore, it was shown that IL-17, 
IL-17F, and IL-22 were dispensable for the development of 
EAE,101,102 although there are also conflicting results.34 Thus, 
both Th1 and Th17 cells can be pathogenic in EAE.
Relatively few data are available on the involvement 
of IL-17 in the pathogenesis of human MS compared with 
mouse EAE or other human diseases, likely due to the dif-
ficulty in obtaining lesion samples. An increased frequency of 
mononuclear cells expressing IL-17 mRNA in the blood and 
spinal fluid of MS patients was reported.103 Transcriptional 
profiling of the genes expressed in MS lesions also demon-
strated upregulation of IL-6 and IL-17.104 Ishizu et al reported 
increased levels of IL-17 and IL-8 in the spinal fluid of patients 
with the opticospinal form of MS, in which neutrophil infil-
tration is more prominent than in conventional MS.105 The 
frequency of Th17 cells but not Th1 cells in the peripheral 
blood was significantly increased in active MS patients.106 In 
another report, the frequency of Th17 cells in the spinal fluid, 
but not in peripheral blood, was increased during relapse.107 
Histologic analysis also showed   expression of IL-17 in active 
lesions.108 As for IL-23, peripheral blood monocyte-derived 
dendritic cells from MS patients had increased expression 
of IL-23p19.109 IL23p19 as well as IL-12/23p40 was also 
detected in active MS lesions.110 Although these results 
suggest the involvement of Th17 cells in the pathogenesis 
of human MS, there have also been reports showing the 
predominance of Th1 cells in   myelin-specific T cells.111,112 
The genetic   association of MS with IL23R polymorphism is 
controversial.113–116 In addition, it was observed that exacer-
bations of MS in patients treated with altered peptide ligand 
were associated with an increased Th1 response.117 MS was 
also exacerbated in patients treated with IFNγ.118 Thus, similar 
to the case of mouse EAE, Th17 cells may not be the only 
pathogenic CD4 T cells in human MS.
Current therapies for autoimmune 
diseases and effect on IL-17  
or Th17 cells
The treatment strategy and prognosis of autoimmune disease 
have greatly changed since the introduction of biologic 
agents, firstly anti-TNFα mAb for RA. Thereafter, anti-IL-6 
and anti-CD20 mAbs and soluble CTLA4-Ig have been dem-
onstrated to be highly effective in RA and are now available 
worldwide.119 TNFα blockers have also been used in the treat-
ment of CD and psoriasis.120,121 However, biological-based 
therapy is sometimes unsuccessful, even when a beneficial 
effect is expected. For example, blocking TNFα exerted 
deleterious effects on MS,122 although local TNFα production 
was shown to be increased in active MS,123 and TNFα has 
various biologic activities that can explain the pathogenesis 
of MS.124 In addition, blocking TNFα was effective in the 
animal model of MS and EAE,125 and TNFα-deficient mice 
were less susceptible to EAE.126 These findings remind us of 
an important lesson, ie, the pathogenesis of animal models 
and real human diseases are not necessarily identical.
There have been studies addressing the effects of   current 
therapies on Th17 responses. Kageyama et al observed a 
significant decline in the level of IL-23 in the serum of RA 
patients after treatment with anti-TNFα mAb, which was sig-
nificantly correlated with improved disease activity, although 
the level of IL-17 was unaffected.127 Yue et al reported, how-
ever, that the percentage of Th17 cells in peripheral blood 
tended to decrease after treatment with another antibody 
against TNFα.128 It was also shown in psoriasis patients that 
TNFα inhibition reduced local expression of Th17-related 
molecules, including IL-23, IL-22, IL-17, CCL20, and 
β-defensin 4.129 These results suggest a downregulatory role 
of TNFα blockers on Th17 responses in vivo, either directly 
or indirectly as the result of reduced inflammation. A mAb 
against IL-6 receptor also effectively controls disease activ-
ity in RA.130 Because IL-6 was shown to be involved in the 
development of Th17 cells, an animal study anticipated that 
Th17 cells are one of the targets of therapy.131 On the other Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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hand, in vitro analysis of human T cells showed that IL-6 
plays a relatively minor role in the development of Th17 cells.3 
In this regard, it is of interest to see the effect of blocking 
IL-1β, because it plays a critical role in the differentiation of 
human Th17 cells. However, IL-1β blockade exerted only a 
modest effect in RA.132 In any case, the effects of IL-1β- or 
IL-6-targeted therapy on Th17 cells have not been reported 
so far. As for MS, IFNβ is widely used for its treatment, and 
some recent studies suggest the involvement of downregu-
lation of Th17 responses. It was reported that Type I IFN 
receptor-deficient mice develop severe EAE with enhanced 
IL-17 production,133 although conflicting data were also dem-
onstrated.134 In vitro experiments showed that IFNβ inhibits 
human Th17 differentiation directly or indirectly via dendritic 
cells.135 However, Drulovic et al reported that while IFNβ 
treatment reduced the level of IFNγ and T-bet, it did not affect 
the level of IL-17 and RORc expression,136 again leaving a 
question about the importance of Th17 cells in MS.
Clinical trials of reagents targeting 
Th17-related molecules  
in autoimmune diseases
A clinical trial is the only way to prove the importance of 
a given target, because it sometimes has results which are 
unexpected from in vitro analysis or animal studies. It was 
revealed that administration of an anti-IL-12/23p40 mAb 
(ABT874) showed a therapeutic effect in patients with CD, 
with no increase of adverse events.137 Treatment with ABT-
874 decreased IFNγ, IL-12, IL-6, and TNFα secretion by 
mononuclear cells in the lamina propria. Impaired IL-17 
production of lamina propria T cells was also reported later.138 
A randomized trial of ustekinumab (CNTO 1275), another 
antihuman IL-12/23p40 mAb, in 104 patients with moderate 
to severe CD also showed a significant effect, even in patients 
who had previously been given antiTNFα mAb.139 In addi-
tion to these antibody-based drugs, a small oral dose of an 
IL-12/23 inhibitor, apilimod mesylate (STA 5326), was tested 
for CD.140 The action of apilimod includes selective inhibition 
of c-Rel translocation, which results in the suppressed tran-
scription of IL-12/23p40 and IL-12p35. The results of a clini-
cal trial showed that apilimod was well tolerated and clearly 
effective in moderate to severe CD. Blocking IL-12/23p40 
is also highly effective for the treatment of psoriasis.141,142 
For instance, a randomized, double-blind study revealed that 
ustekinumab was so effective that 66% of patients receiving 
45 mg of ustekinumab but only 3% of patients receiving pla-
cebo achieved a 75% improvement of the psoriasis area and 
severity index.143 Furthermore, it was recently reported that 
ustekinumab was even more effective than the soluble TNFα 
receptor, etanercept, for the treatment of psoriasis.144 These 
results indicate that IL-12/23p40 plays a critical role in the 
pathogenesis of CD and psoriasis. However, as these reagents 
do not only affect Th17 responses, possible involvement of 
IFNγ or Th1 responses in the pathogenesis is not excluded. It 
is also possible that IL-12 or IL-23 participate in the disease 
pathogenesis in a T cell-independent manner.
In contrast with the success in CD and psoriasis, a clinical 
trial of ustekinumab had disappointing results in MS. Up to 
180 mg of ustekinumab was administered weekly until three 
weeks, and every four weeks thereafter. The number of new 
lesions was evaluated at week 23, but there was no reduction of 
lesions in the treatment group. Furthermore, there was no dif-
ference in the number of clinical or objective relapses.145 One 
may argue that the treatment should be applied at an early stage 
of the disease. However, administration of   anti-IL-12/23p40 
mAb as well as anti-IL-23p19 mAb was effective in EAE 
even after onset.146 Furthermore, the apparent clinical effect 
of blocking IL-12/23p40 in psoriasis and CD, irrespective 
of the duration of the disease, also argues against the idea. 
Therefore, it is more reasonable to assume that the pathology 
of MS, especially in the context of the cytokine network, is 
largely different from CD or psoriasis. This also reminds us of 
the different effect of TNFα blockade between MS and CD or 
psoriasis. As for RA, there has been no report of the therapeutic 
effect of targeting IL-12/23p40. However, the results of a 
Phase I trial of anti-IL-17 mAb (LY2439821) in the treatment 
of RA were recently published.147 Although a certain degree 
of improvement of disease activity has been shown, the effect 
does not seem to be as strong as for TNFα blockers. However, 
it might be too early to draw conclusions, because of the small 
subject number and relatively high improvement rates in the 
placebo group. There is another anti-IL-17 mAb (AIN457) 
being tested for RA, but detailed results of the trial have not 
been published so far.119 In view of the biologic functions of 
IL-17, blocking IL-17 may exert a clearer beneficial effect in 
suppression of joint destruction during long-term follow-up. 
In this regard, future combination therapy including a TNFα 
blocker is of particular interest. To date, there has been no 
report of the effects of blocking IL-17 or other Th17-related 
cytokines in other human autoimmune diseases.
Conclusions
The discovery of IL-17 has led to novel insights into the 
pathogenesis of several autoimmune diseases, and the 
importance of IL-17 has been demonstrated in various animal 
models. However, it has become clear that there is a large Journal of Inflammation Research 2010:3 submit your manuscript | www.dovepress.com
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variation in the therapeutic effect of targeting IL-17-related 
molecules in human autoimmune diseases. Further clinical 
trials might clarify the whole picture. At the same time, these 
findings also provoke the need for a better understanding of 
the differences between human and mouse immune systems, 
and for the development of better disease models, in order 
to avoid unnecessary clinical trials with their inevitable risk 
of adverse events.
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